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e216 LettersTRM then initiated cytotoxic responses against
keratinocytes that resulted in epidermal necrolysis.
Further analyses are needed to reveal the precise
mechanisms.
This case shows that TEN can be evoked even
in the absence of circulating T cells, and emphasizes
the importance of TRM during skin inflammation
including drug hypersensitivity.
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E-mail: keisuke.nagao@nih.govFig 1. Varicella zoster viruseinduced generalized pustular
psoriasis in an infant. Pustulosis and crusts on the face,
trunk, and limbs are seen.REFERENCES
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pustular psoriasis in a baby with heterozygous
IL36RN mutation
To the Editor: A 2-month-old otherwise healthy boy
presented with erythema and pustules without
vesicles on the face, trunk, and all limbs. There was
no improvement following treatment with oral
antibiotics 3 weeks earlier. On admission to our
hospital he had a slight fever and a generalized
crusted pustular eruption (Fig 1). Laboratory
data showed the following abnormal values:
white blood cell count 19.14 3 109/L (normal range:
7-15 3 109/L); C-reactive protein level 108.5 mg/L
(normal range: \3 mg/L). Bacterial culture of
the pustules and microscopy for fungal infection
were negative. Histopathologic examination of a
skin biopsy specimen revealed spongiosis with
neutrophil infiltration in the upper epidermis (Fig 2).
The pustulosis did not improve with application
of a potent topical steroid and vitamin D3-containing
ointment. Oral cyclosporine was started and
gradually increased to 4 mg/kg at 64 days from the
disease onset. One week later, the pustules
had almost cleared. Administration of 4 mg/kg
cyclosporine was continued for more than 9
months. Extensive pustules reappeared with
development of an upper respiratory tract infection
Fig 2. Varicella zoster viruseinduced generalized pustular
psoriasis: hematoxylin and eosin staining of the pustules;
Bar: 40 m.
Fig 3. Varicella zoster viruseinduced generalized pustular
psoriasis: IL36RN sequence data of the patient and
the parents. Arrow indicates the heterozygous c.28C[T
mutation.
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There was no family history of a similar eruption.
Before the skin manifestations developed, chicken-
pox was diagnosed in the patient’s brother. Serum
anti-varicella zoster virus (anti-VZV) immunoglo-
bulin M tested negative in the baby initially but was
positive 46 days after the disease onset. Anti-VZV
immunoglobulin G antibodies were positive and
thought to be derived from the baby’s mother.
There was no serologic evidence of herpes simplex
virus infection.After ethical approvalwas granted,written informed
consent was obtained from the baby’s parents in
compliancewith theDeclarationofHelsinki. The entire
coding regions of IL36RN including the exon/intron
boundaries were sequenced using genome DNA
samples from the patient and his parents. The patient
andhis father had a heterozygous c.28C[T (p.Arg10X)
mutation in IL36RN, one of the generalized pustular
psoriasis (GPP)-causing founder mutations in the
Japanese cohort, whereas his mother did not have an
IL36RNmutation (Fig 3).1
Diagnosis was VZV-induced GPP, a rare type of
psoriasis that periodically recurs. Infection is one of its
triggers. Mutation of IL36RN, which encodes
interleukin-36 receptor antagonist (IL-36RN), has
been associated with GPP in both its heterozygous
and homozygous forms.1-3 IL-36 is not present in
normal skin but is induced by inflammatory cytokines
including tumor necrosis factor- (TNF-).4 When
functional IL-36RN is underproduced, IL-36 can induce
neutrophil-rich infiltration. TNF- is elevated in the
blood of VZV-infected individuals.5 It is possible that
this patient could not produce enough IL-36RN to
antagonize the excessive IL-36 induced by VZV
infection, an imbalance that resulted in GPP.
To our knowledge, this is the first report of
VZV-induced GPP and of GPP triggered by infection
in a patient with a heterozygous IL36RN mutation.
Clinicians should consider IL-36RN deficiency in
the setting of prolonged viral-induced generalized
pustulosis.
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Fig 1. Chronic recurrent multifocal osteomyelitis.
Onycholysis, nail pits, oil spots, and discoloration of the
nails as well as erythema, hyperkeratosis, pustules on the
sole of our 9-year-old female patient.
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To the Editor: A 9-year-old girl presented with a
15-month history of severe joint pain limited to the
right ankle. She had been treated for fatigue
fracture and epiphysitis, but continued to require
the use of crutches. The patient had pronounced
muscular atrophy of the right leg, swelling and
hyperthermia at the heel, and plantar pustulosis.
She had mild paronychia on most fingers of the right
hand and progressive changes in the fingernails,
which were characteristic of nail psoriasis (Fig 1).
Thus, psoriatic arthritis or osteitis was suspected, and
oral naproxen (200 mg twice daily) therapy was
prescribed. Whole-body magnetic resonance
imaging (MRI) was performed and demonstrated
inflammatory bone lesions, osteolysis, and sclerotic
lesions (Fig 2). Laboratory parameters were within
normal ranges. Her family history was unremarkable
for similar cutaneous or musculoskeletal pathology.
Chronic recurrent multifocal osteomyelitis (CRMO)
with multifocal bone lesions, plantar pustulosis, and
nail involvement was diagnosed. Oral methotrexate
therapy (15 mg/week) was initiated and naproxen
was continued. After 6 months, the joint pain
resolved, and muscular atrophy, palmar pustulosis,
and nail lesions improved.
CRMO is an acquired aseptic autoinflammatory
bone disease that presents predominantly in girls
and is characterized by pain that is worse at
night, with or without fever. Typically there is a
discrepancy between the mild symptoms and
extensive bone inflammation. Sedimentation rate
and C-reactive protein (CRP) valuesmay be elevated,while the white blood cell count and other
laboratory parameters are usually normal. The
diagnosis of CRMO is mainly reliant on imaging
studies. Conventional radiography initially shows
osteolytic bone lesions with development of
peripheral sclerosis in the course of the disease.
MRI may show early lesions such as edema of
bone marrow and inflammation of soft tissue. In
order to diagnose CRMO, two major or one major
and three minor criteria must be fulfilled.1-3 Major
criteria are osteolytic or sclerotic bone lesions,
multifocal bone lesions, palmoplantar pustulosis or
psoriasis, and sterile bone biopsy with signs of
inflammation, fibrosis, or both. Minor criteria are
normal blood cell count, good general health,
slightly to moderately elevated CRP and erythrocyte
sedimentation rate, clinical course of at least 6
months, hyperostosis, association with autoinflam-
matory diseases other than palmoplantar pustulosis
or psoriasis, and a first- or second-degree relative
with nonbacterial osteitis, or autoimmune or auto-
inflammatory disorders.
Some authors believe CRMO to be a juvenile
variant of the SAPHO syndrome (synovitis, acne,
pustulosis, hyperostosis, osteitis). However, to
what extent CRMO and SAPHO present a spectrum
of one disease or separate entities remains
controversial.2
There is no standard therapy of CRMO; however,
nonsteroidal antiinflammatory drugs (NSAIDs) are
considered to be first-line treatment with a favorable
response rate in up to 80% of patients. Patients
may require therapy to control skin and bone
lesions, and NSAIDs can be used during attacks or
to prevent attacks.5 NSAID therapy is usually
continued until patients are symptom-free for at least
3 months. When NSAID therapy is inadequate,
primary treatment options are bisphosphonates and
tumor necrosis factor antagonists,5 and strong data
